Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm

Leukemia Research

Volumn 32, Issue 12, 2008, Pages 1931-1935

  Fend, Falko ^a,b   Horn, Thomas ^b   Koch, Ina ^b   Vela, Teresa ^b   Orazi, Attilio ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical chronic myeloid leukemia; Atypical CML; Bone marrow trephine biopsy; JAK2 mutation; Myelodysplastic myeloproliferative neoplasms

Indexed keywords

JANUS KINASE 2; PARAFFIN;

ADULT; AGED; ALLELE; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC MYELOPROLIFERATIVE NEOPLASM; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

AMINO ACID SUBSTITUTION; BLAST CRISIS; BLOOD CELL COUNT; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MASTOCYTOSIS; NEUTROPHILS; PHILADELPHIA CHROMOSOME; WORLD HEALTH ORGANIZATION;

EID: 51649120030     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.04.024     Document Type: Article

References (20)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H., et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol 87 (1994) 746-754
2. Vardiman J.W., Bain B., Inbert M., Brunning R.D., Pierre R., and Flandrin G. Atypical chronic myeloid leukemia. In: Jaffe E., Harris N.L., Stein H., and Vardiman J. (Eds). WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon 53-57
3. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
4. Kurzrock R., Bueso-Ramos C.E., Kantarjian H., Freireich E., Tucker S.L., Siciliano M., et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 19 (2001) 2915-2926
5. Breccia M., Biondo F., Latagliata R., Carmosino I., Mandelli F., and Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica 91 (2006) 1566-1568
6. Onida F., Ball G., Kantarjian H.M., Smith T.L., Glassman A., Albitar M., et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 95 (2002) 1673-1684
7. Jelinek J., Oki Y., Gharibyan V., Bueso-Ramos C., Prchal J.T., Verstovsek S., et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106 (2005) 3370-3373
8. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
9. Levine R.L., Loriaux M., Huntly B.J.P., Loh M.L., Beran M., Stoffregen E., et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106 (2005) 3377-3379
10. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106 (2005) 1207-1209
11. Szpurka H., Tiu R., Murugesan G., Aboudola S., Hsi E.D., Theil K.S., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108 (2006) 2173-2181
12. Orazi A., Chiu R., O'Malley D.P., Czader M., Allen S.L., An C., et al. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol 19 (2006) 1536-1545
13. Horn T., Kremer M., Dechow T., Pfeifer W.M., Geist B., Perker M., et al. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases. J Mol Diagn 8 (2006) 299-304
14. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
15. Kremer M, Horn T, Koch I, Pfeifer WM, Tzankov A, Gattenlöhner S, et al. Quantitation of the JAK2 V617F mutation in microdissected bone marrow trephines: equal mutation load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol; in press.
16. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology 74 2 (2007) 97-114 Review
17. Johan M.F., Goodeve A.C., Bowen D.T., Frew M.E., and Reilly J.T. JAK2 V617F mutation is uncommon in chronic myelomonocytic leukaemia. Br J Haematol 130 (2005) 968
18. Lea N.C., Lim Z., Westwood N.B., Arno M.J., Gaken J., Mohamedali A., et al. Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia. Leukemia 20 (2006) 1324-1326
19. Safley A.M., Sebastian S., Collins T.S., Tirado C.A., Stenzel T.T., Gong J.Z., et al. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer 40 (2004) 44-50
20. Wittman B., Horan J., Baxter J., Goldberg J., Felgar R., Baylor E., et al. A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leuk Res 28 Suppl. 1 (2004) S65-S69